Nucleic Acid Complex

• US 20080206869A1
• Filed: 01/23/2006
• Published: 08/28/2008
• Est. Priority Date: 01/24/2005
• Status: Abandoned Application

• Current Assignee: Avaris AB
• Original Assignee: Avaris AB
• Inventors: Smith, Edvard, Svahn, Mathias, Simonson, Oscar
• Application Number:
  US11/814,646
• Publication Number:
  US 20080206869A1
• Time in Patent Office: Days
• US Class Current: 435/440
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/3181 Peptide nucleic acid, PNA
• CPC Class Codes: C12N 2310/3183 Diol linkers, e.g. glycols or propanediols
• CPC Class Codes: C12N 2310/3231 having an additional ring, e.g. LNA, ENA
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

The present invention relates to modification of nucleic acids for specific delivery in vitro and in vivo. More specifically, the present invention relates to modification of RNA or DNA molecules in order to add functions in terms of delivery and specificity to RNA interference or antisense technology. A specific binding domain is incorporated into the nucleic acid to which a complementary nucleic acid, conjugated to a biologically active molecule, can hybridize.

Claims

1. A complex utilizing one or more functional entities (FEs), said FE(s) being capable of preventing degradation and/or removal of said complex, increasing the activity of said complex and/or increasing the transfer of said complex;

extracellularly (within an organism), transcellularly (across a cellular membrane) and/or intracellularly (into different locations within a cell), characterized in that said complex comprises a short interfering RNA (siRNA) molecule, wherein said siRNA molecule comprises a first and a second strand and said siRNA molecule is modified in the following way;

at least one anchor-binding domain is incorporated into any one of the two strands of the siRNA molecule, said anchor-binding domain being a nucleic acid or analog thereof,

at least one anchor sequence is hybridized to said anchor-binding domain, said anchor sequence being a nucleic acid or analog thereof, and

at least one functional entity (FE) is linked to said at least one anchor sequence, said FE(s) being one or more biologically active molecule(s).

2. A complex according to claim 1, wherein the anchor-binding domain has one or more mismatches with respect to the other strand.

3. A complex according to claim 1, wherein the anchor-binding domain has 1-7 mismatches with respect to the other strand.

4. A complex according to claim 1, wherein the anchor-binding domain is a part of the siRNA molecule.

5. A complex according to claim 1, wherein the anchor-binding domain comprises up to 15 nucleotides.

6. A complex according to claim 1, wherein the anchor-binding domain comprises 3-12 nucleotides.

7. A complex according to claim 1, wherein the anchor-binding domain comprises 4-8 nucleotides.

8. A complex according to claim 1, wherein said anchor is a locked nucleic acid (LNA), peptide nucleic acid (PNA) or derivate thereof.

9. A complex according to claim 1, wherein the sense strand of the siRNA molecule acts as binding domain for the anchor sequence.

10. A complex according to claim 1, wherein the antisense strand of the siRNA molecule acts as binding domain for the anchor sequence.

11. A complex according to claim 1, wherein the siRNA molecule has a maximum length of 35 base pairs.

12. A complex according to claim 1, wherein the siRNA molecule has 3′

and/or 5′

overhangs of 1 to 12 nucleotides.

13. A complex according to claim 1, wherein the siRNA molecule has 3′

and/or5′

overhangs of 2 to 5 nucleotides.

14. A complex according to claim 1, wherein the siRNA molecule is chemically modified.

15. A complex according to claim 1, wherein the anchor-binding domain is an extension at either end of the sense or the antisense strand of the siRNA molecule.

16. A complex according to claim 1, wherein the complex comprises a cleavable linker molecule between said at least one FE and said at least one anchor sequence.

17. A complex according to claim 1, wherein the complex comprises a cleavable linker molecule between said at least one FE and said at least one anchor sequence and said linker comprises a disulphide bridge.

18. A complex according to claim 1, wherein the anchor sequence comprises a cleavable linker.

19. A complex according to claim 1, wherein the anchor sequence comprises a cleavable linker and said linker comprises a disulphide bridge.

20. A complex according to claim 1, wherein the anchor sequence is extended with at least one anchor-binding domain.

21. A method for transferring one or more functional entities (FEs) across a cellular membrane and into different locations within a cell wherein a complex according to claim 1 is used for transfection.

62. A cell transfected with the complex according to claim 1.

22. A method for making a complex that utilises one or more functional entities (FEs), said FE(s) being capable of preventing degradation and/or removal of said complex, increasing the activity of said complex and/or increasing the transfer of said complex;

extracellularly (within an organism), transcellularly (across a cellular membrane) and/or intracellularly (into different locations within a cell), said complex comprises a short interfering RNA (siRNA) molecule and said siRNA molecule comprises a first and a second strand and wherein the method comprises the following steps;

introducing at least one anchor-binding domain into the siRNA molecule, said anchor-binding domain being a nucleic acid or analog thereof,

hybridizing at least one anchor sequence to said anchor-binding domain, said anchor sequence being a nucleic acid or analog thereof, and

linking at least one functional entity (FE) to said at least one anchor sequence, said FE(s) being one or more biologically active molecule(s).

23. A complex utilizing one or more functional entities (FEs), said FE(s) being capable of preventing degradation and/or removal of said complex, increasing the activity of said complex and/or increasing the transfer of said complex;

extracellularly (within an organism), transcellularly (across a cellular membrane) and/or intracellularly (into different locations within a cell), characterized in that said complex comprises a short hairpin RNA (shRNA) molecule, wherein said shRNA molecule has a double stranded region and a hairpin loop and said shRNA molecule is modified in the following way;

at least one anchor-binding domain is incorporated into the shRNA molecule, said anchor-binding domain being a nucleic acid or analog thereof,

at least one anchor sequence is hybridized to said anchor-binding domain, said anchor sequence being a nucleic acid or analog thereof, and

at least one functional entity (FE) is linked to said at least one anchor sequence, said FE(s) being one or more biologically active molecule(s).

24. A complex according to claim 23, wherein the anchor-binding domain is a part of the shRNA molecule.

25. A complex according to claim 23, wherein the anchor-binding domain comprises up to 15 nucleotides.

26. A complex according to claim 23, wherein the anchor-binding domain comprises 3-12 nucleotides.

27. A complex according to claim 23, wherein the anchor-binding domain comprises 4-8 nucleotides.

28. A complex according to claim 23, wherein said anchor is a locked nucleic acid (LNA), peptide nucleic acid (PNA) or derivate thereof.

29. A complex according to claim 23, wherein the double stranded region of the shRNA molecule has a maximum length of 35 base pairs.

30. A complex according to claim 23, wherein the shRNA molecule has 3′

and/or5′

overhangs of 1 to 12 nucleotides.

31. A complex according to claim 23, wherein the shRNA molecule has 3′

and/or5′

overhangs of 2 to 5 nucleotides.

32. A complex according to claim 23, wherein the shRNA molecule is chemically modified.

33. A complex according to claim 23, wherein the anchor-binding domain is an extension at either end of the shRNA molecule.

34. A complex according to claim 23, wherein the anchor-binding domain is in the hairpin loop of the shRNA molecule.

35. A complex according to claim 23, wherein the anchor-binding domain is in one of the two strands of the double stranded region of the shRNA molecule.

36. A complex according to claim 23, wherein the anchor-binding domain is partly in the hairpin loop and partly in one of the two strands of the double stranded region of the shRNA molecule.

37. A complex according to claim 35, wherein the anchor binding domain has one or more mismatches with respect to the other strand of the double stranded region of the shRNA molecule.

38. A complex according to claim 35, wherein the anchor-binding domain has 1-7 mismatches with respect to the other strand of the double stranded region of the shRNA molecule.

39. A complex according to claim 23, wherein the complex comprises a cleavable linker molecule between said at least one FE and said at least one anchor sequence.

40. A complex according to claim 23, wherein the complex comprises a cleavable linker molecule between said at least one FE and said at least one anchor sequence and said linker comprises a disulphide bridge.

41. A complex according to claim 23, wherein the anchor sequence comprises a cleavable linker.

42. A complex according to claim 23, wherein the anchor sequence comprises a cleavable linker and said linker comprises a disulphide bridge.

43. A complex according to claim 23, wherein the anchor sequence is extended with at least one anchor-binding domain.

44. A method for transferring one or more functional entities (FEs) across a cellular membrane and into different locations within a cell wherein a complex according to claim 23 is used for transfection.

45. A method for making a complex that utilises functional entities (FEs), said FE(s) being capable of preventing degradation and/or removal of said complex, increasing the activity of said complex and/or increasing the transfer of said complex;

extracellularly (within an organism), transcellularly (across a cellular membrane) and/or intracellularly (into different locations within a cell), said complex comprises a short hairpin RNA (shRNA) molecule and said shRNA molecule has a double stranded region and a hairpin loop, wherein the method comprises the following steps;

introducing at least one anchor-binding domain into the shRNA molecule, said anchor-binding domain being a nucleic acid or analog thereof,

hybridizing at least one anchor sequence to said anchor-binding domain, said anchor sequence being a nucleic acid or analog thereof, and

linking at least one functional entity (FE) to said at least one anchor sequence, said FE(s) being one or more biologically active molecule(s).

46. A complex utilizing one or more functional entities (FEs), said FE(s) being capable of preventing degradation and/or removal of said complex, increasing the activity of said complex and/or increasing the transfer or said complex;

extracellularly (within an organism), transcellularly (across a cellular membrane) and/or intracellularly (into different locations within a cell), characterized in that said complex comprises an AS (antisense) molecule, wherein said AS molecule is modified in the following way;

at least one anchor-binding domain is incorporated or attached to the AS molecule, said anchor-binding domain being a nucleic acid or analog thereof,

at least one anchor sequence is hybridized to said anchor-binding domain, said anchor sequence being a nucleic acid or analog thereof, and

at least one functional entity (FE) is linked to said at least one anchor sequence, said FE(s) being one or more biologically active molecule(s).

47. A complex according to claim 46, wherein the anchor-binding domain is a part of the AS molecule.

48. A complex according to claim 46, wherein the anchor-binding domain comprises up to 15 nucleotides.

49. A complex according to claim 46, wherein the anchor-binding domain comprises 3-12 nucleotides.

50. A complex according to claim 46, wherein the anchor-binding domain comprises 4-8 nucleotides.

51. A complex according to claim 46, wherein said anchor is a locked nucleic acid (LNA), peptide nucleic acid (PNA) or derivate thereof.

52. A complex according to claim 46, wherein the antisense molecule has a maximum length of 35 bases.

53. A complex according to claim 46, wherein the AS molecule is chemically modified.

54. A complex according to claim 46, wherein the anchor-binding domain is an extension at either end of the strand of the AS molecule.

55. A complex according to claim 46, wherein the complex comprises a cleavable linker molecule between said at least one FE and said at least one anchor sequence.

56. A complex according to claim 46, wherein the complex comprises a cleavable linker molecule between said at least one FE and said at least one anchor sequence and said linker comprises a disulphide bridge.

57. A complex according to claim 46, wherein the anchor sequence comprises a cleavable linker.

58. A complex according to claim 46, wherein the anchor sequence comprises a cleavable linker and said linker comprises a disulphide bridge.

59. A complex according to claim 46, wherein the anchor sequence is extended with at least one anchor-binding domain.

60. A method for transferring one or more functional entities (FEs) across a cellular membrane and into different locations within a cell wherein a complex according to claim 46 is used for transfection.

61. A method for making a complex that utilises functional entities (FEs), said FE(s) capable of preventing degradation and/or removal of said complex, increasing the activity of said complex and/or increasing the transfer of said complex;

extracellularly (within an organism), transcellularly (across a cellular membrane) and/or intracellularly (into different locations within a cell) and said complex comprises an AS (antisense) molecule, wherein the method comprises the following steps;

incorporating or attaching at least one anchor-binding domain to the AS molecule, said anchor-binding domain being a nucleic acid or analog thereof,

hybridizing at least one anchor sequence is to said anchor-binding domain, said anchor sequence being a nucleic acid or analog thereof, and

linking at least one functional entity (FE) to said at least one anchor sequence, said FE(s) being one or more biologically active molecule(s).

63. A kit comprising components for producing a complex capable of transferring one or more siRNA, shRNA or AS molecules across a cellular membrane (intracellularly, extracellularly and/or transcellularly) and into different locations within a cell, said kit comprising at least one siRNA, shRNA and/or AS molecule, at least one anchor-binding domain, at least one anchor sequence being able to hybridize to said anchor-binding domain, and at least one functional entity (FE) linked to said anchor-binding domain, said FE(s) being one or more biologically active molecule(s).